• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Insclisiran significantly decreases LDL cholesterol in heterozygous familial hypercholesterolemia patients

byHarsh ShahandDeepti Shroff Karhade
April 7, 2020
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Inclisiran, a small interfering RNA, therapy was shown to significantly lower levels of low-density lipoprotein (LDL) cholesterol compared to the placebo in adults with heterozygous familial hypercholesterolemia.

2. The reduction in LDL cholesterol levels, via inclisiran therapy, was shown to be similar to the reduction achieved with proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody therapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Current pharmacologic management of familial hypercholesterolemia includes high intensity statins and monoclonal antibodies directed against PCSK9. Both therapies have been shown to reduce LDL cholesterol but require frequent dosing regimens. The ORION-9 trial evaluated inclisiran, a novel small interfering RNA therapeutic that also acts on PCSK9, in a large patient cohort of adults with heterozygous familial hypercholesterolemia who had been treated with a maximally accepted statin therapy dose. The study found a significant decrease in LDL cholesterol from baseline in the inclisiran group compared to the placebo group.

Of note, while the majority of the patients were also taking a statin and ezetimibe, the regimens across participants was not consistent. Furthermore, the combined effects of various statins, ezetimibe, and inclisiran on LDL cholesterol was not separately analyzed. Nonetheless, this study is strengthened by the diagnostic measures used to assess the effect of inclisiran on LDL cholesterol levels. For physicians, these findings provided evidence for another therapy for patients who have failed high intensity statins and do not want frequent dosing regimens.

Click to read the study in NEJM

Relevant Reading: Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

RELATED REPORTS

Treat-to-target approach non-inferior to high-dose statin therapy in patients with coronary artery disease

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

In-Depth [randomized controlled trial]: This phase-3 randomized control trial enrolled 482 patients in a multicenter study from 46 sites in eight different countries. The inclusion criteria included adults (≥ 18 years of age) diagnosed with familial hypercholesterolemia based on genetic confirmation and an LDL cholesterol level of at least 100 mg per deciliter (mg/dl). The exclusion criteria included patients who had received PCSK9 monoclonal antibody therapy. The patients were randomized to the inclisiran therapy or placebo therapy in a 1:1 ratio. The primary outcome of the study was two-fold. First, the study determined the percent change from baseline of the LDL cholesterol level at day 510. Second, the study determined the time-adjusted percent change from baseline in the LDL cholesterol level between day 90 and day 510. The authors hypothesized that the inclisiran therapy would lower the LDL cholesterol level more quickly than the placebo group. Additionally, secondary outcomes included mean absolute change from baseline in the LDL cholesterol at day 510. Patients in the inclisiran group, collectively, experienced an LDL reduction of 39.7% (95% confidence interval [CI], −43.7 to −35.7) from baseline.. During the same time, patients in the placebo group experienced an 8.2% (95% CI 4.3 to 12.2) increase in LDL cholesterol. Taken together, the percentage change difference between both groups was 47.9% (95% CI, −53.5 to −42.3). In regard to time-adjusted percent change between day 90 and day 510, patients in the inclisiran group experienced a 38.1% (95%CI, −41.1 to −35.1) decrease compared to a 6.2% (95% CI, 3.3 to 9.2) increase in the placebo group. Finally, the mean absolute change at day 510 in the inclisiran group was a 59.0 mg/dl decrease (95% CI, −64.8 to −53.2) compared to a 9.9 mg/dl increase (95% CI, 4.1 to 15.8) in the placebo group.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: familial hypercholesterolemiahyperlipidemiainclisirinLDLsmall interfering RNA (siRNA)
Previous Post

2 Minute Medicine Rewind April 6, 2020

Next Post

Conversion of pharyngeal specimens from SARS-nCoV-2-positive to negative may not correlate with end of viral shedding

RelatedReports

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Treat-to-target approach non-inferior to high-dose statin therapy in patients with coronary artery disease

March 10, 2023
Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]
Cardiology

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

November 22, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

November 16, 2021
#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors
StudyGraphics

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

July 15, 2021
Next Post
Initial data on the viability of SARS-CoV-2 in aerosol and on surfaces

Conversion of pharyngeal specimens from SARS-nCoV-2-positive to negative may not correlate with end of viral shedding

2 Minute Medicine Rewind July 29, 2019

Inhibition of inflammation through interleukin pathway may be protective against anemia

Radiological findings of COVID-19 pneumonia in Wuhan, China

Lopinavir-ritonavir not associated with clinical benefit in patients with severe COVID-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abnormal menstruation may be associated with worse cardiometabolic outcomes later in life
  • Past infection with pre-omicron variants of COVID-19 protects against re-infection
  • No difference in complete expulsion of intrauterine device between early and standard interval postpartum placement
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options